• Providing a universal, lexicon-driven risk stratification system for adnexal masses on ultrasound.
• Directly mapping sonographic findings to specific clinical management algorithms.
• Replacing chaotic free-text radiology reports with actionable, universally understood categories (like BI-RADS for breast).

• O-RADS beautifully synthesizes the "IOTA Simple Rules" and the "IOTA ADNEX model" into one cohesive management algorithm.
• A completely anechoic "simple cyst" in a premenopausal woman is O-RADS 2, even up to 10cm! Classic radiology used to flag 5cm cysts as highly suspicious; O-RADS stops this over-referral.
• Any irregularity in solid components, or vascularity (Color Score 4) in solid tissues, radically spikes the risk into O-RADS 5.

• O-RADS 1 & 2: Routine care. Follow-up only if symptomatic or pre-specified sizes. Handled by primary care / general gyn.
• O-RADS 3: Conservative management via ultrasound surveillance (e.g., 3-6 months), or consultation with general gynecologist for benign excision if symptomatic.
• O-RADS 4: Management by a gynecologist in consultation with a Gyn Oncologist, OR perform Pelvic MRI (O-RADS MRI score) to re-stratify.
• O-RADS 5: Mandatory referral to a Gynecologic Oncologist. Avoid surgical spillage at all costs.

Following the unprecedented success of BI-RADS for mammography, the ACR partnered with the IOTA group to create O-RADS, finally bringing order to the notoriously subjective landscape of pelvic ultrasonography.